氨磺必利与喹硫平治疗精神分裂症患者的疗效和安全性

Comparative analysis of efficacy and safety of amisulpride and quetiapine in the treatment of schizophrenia

目的比较氨磺必利与喹硫平治疗精神分裂症的疗效和安全性。方法随机选取2016年8月~2018年8月我院精神分裂症患者60例,随机分为氨磺必利组(30例)和喹硫平组(30例),比较两组患者的PNASS评分、临床疗效、不良反应发生情况。结果治疗前,两组患者的一般精神病理、阳性症状、阴性症状评分及PANSS总分之间无明显差异(P>0.05)两组患者治疗后的一般精神病理、阳性症状、阴性症状评分及PANSS总分均显著低于治疗前(P<0.05),但组间没有差异;氨磺必利组和喹硫平组的总有效率无明显差异(P>0.05)。氨磺必利组的不良反应发生率23.3%(7/30)显著低于喹硫平组43.3%(13/30)(P<0.05)。结论氨磺必利与喹硫平治疗精神分裂症的疗效相当,但氨磺必利较喹硫平不良反应少。

Objective To compare the efficacy and safety of amisulpride and quetiapine in the treatment of schizophrenia. Methods Sixty cases of patients with schizophrenia in our hospital from August 2016 to August 2018 were selected and randomly divided into two groups :the amisulpride group(30 cases)and the quetiapine group(30 cases). The PNASS scores,clinical efficacy,occurrances of adverse reactions in the two groups were compared. Results Before treatment,There were no difference in general psychopathology,positive symptoms,and negative symptom scores and total scores of PANSS between the two groups(P>0.05). After treatment,the general psychopathology,positive symptoms,negative symptom scores and PANSS scores in both of two groups were significantly reduced than before treatment(P<0.05),there are no difference between two groups. The difference of total effective rate of treatment between the amisulpride group(90.0%)and quetiapine group(86.7%)was not difference(P>0.05). The incidence of adverse reactions of the amisulpride group(23.3%)was significantly lower than the quetiapine group(43.3%)(P<0.05). Conclusion Amisulpride is equivalent to quetiapine in the treatment of schizophrenia,but amisulpride is safer than quetiapine.